جست‌وجوی استاد و پژوهشگر

• Molecular Medicine
• Respiratory Diseases
• Cellular Metabolism
• +۳ مورد دیگر

Charalambos Michailoudis is an Assistant Professor at Imperial College London's Faculty of Medicine, specializing in molecular mechanisms of respiratory diseases. He holds a PhD in Clinical Medicine Research (2009) and MSc in Molecular Life Sciences (2005) from King's College London. Education PhD in Clinical Medicine Research, Imperial College London (2009) MSc in Molecular Life Sciences (Distinction), King's College London (2005) BSc in Medical Biochemistry, King's College London (2003) His research focuses on mitochondrial biology, oxidative stress, and metabolic reprogramming in respiratory diseases like COPD and asthma. Recent work examines mitochondrial transfer mechanisms and endoplasmic reticulum stress regulation in airway cells. Key publication trends include stem cell-mediated mitochondrial repair (2022-2018), epigenetic regulation of antioxidant pathways (2014), and inflammatory signaling in airway diseases (2011). Collaborations span NHLI, British Heart Foundation, and Shenzhen Hospital. Scientific Awards National Heart and Lung Institute Doctoral Scholarship (2005) European Respiratory Society (ERS) Young Scientist Sponsorship (2010, 2020) British Lung Foundation Travel Fellowship (2012) Asthma UK Travel Award (2010) ERS Travel Bursary (2020) Michailoudis serves on the Biomolecules Journal's Topical Advisory Panel and the ERS College of Experts, contributing to peer review and research evaluation. His work on mitochondrial dynamics in COPD and asthma has received funding from the Wellcome Trust, Dunhill Trust, and Shenzhen's Sanming Project.

Ramsay Mcfarlaneمشاهده پروفایل

مدرس ارشد

• Cancer Genetics
• Genome Stability
• Stem Cell Biology
• +۵ مورد دیگر

Dr. Ramsay Mcfarlane serves as Senior Lecturer in Biomedical Sciences (Medical & Molecular Genetics) at Bangor University's North Wales Medical School, where he concurrently holds positions as Research Group Leader and Deputy Head of School for Research. His work focuses on elucidating how cancer cells exploit germline and stem cell genes to manipulate cell proliferation and genome dynamics, with the ultimate goal of developing novel diagnostic tools and therapeutic interventions for cancer patients through the identification of druggable targets and biomarkers. Education: Ph.D. in Medical Genetics, Liverpool University, UK (Supervised by Prof. John Saunders) Dr. McFarlane's research program centers on cancer genetics and genome stability mechanisms, specifically investigating germ line genes, cancer testis antigens, meiosis, and telomere biology in human cancer cells, model organisms, and pluripotent stem cells. His group has demonstrated non-uniform DNA replication failure across the genome and identified conserved protein complexes governing telomere maintenance in cancer progression. This work has yielded significant discoveries in cancer-specific biomarker genes with direct applications for patient stratification, early diagnosis, and development of both conventional and immunotherapeutic drug targets. Analysis of his recent publications (2017-2022) reveals a cohesive research trajectory focused on molecular mechanisms of genome instability, with particular emphasis on Translin/Trax complexes, Brachyury signaling, and germ cell-specific gene networks like TEX19. These studies consistently bridge fundamental molecular biology with translational oncology, highlighting novel vulnerabilities in cancer cell regulation that inform therapeutic development. Scientific Awards: NIH Postdoctoral Fellowship at Fred Hutchinson Cancer Research Center, Seattle, USA Dr. McFarlane has supervised 30 research students and projects while securing major funding from the MRC, Wellcome Trust, Royal Society, BBSRC, North West Cancer Research, Cancer Research Wales, NHS, and the Saudi Arabian Government. Current initiatives include the Wales Cancer Research Centre (2020-2025) and the application of cancer-testis genes to address unmet clinical needs in oncology (2023-2027), demonstrating sustained impact in translational cancer research. He established the North West Cancer Research Institute at Bangor University in partnership with the regional cancer charity, creating a dedicated research ecosystem focused on genome dynamics in cancer. His laboratory features state-of-the-art facilities including human cancer/embryonic stem cell culture suites, confocal microscopy, fluorescence-activated cell sorting, and advanced molecular biology technologies, enabling comprehensive investigation of cancer stem cell mechanisms and therapeutic targeting.

Tanja A. Gruberمشاهده پروفایل

استاد

• Pediatric Hematology-Oncology
• Molecular Pathogenesis of High-Risk Pediatric Leukemias
• Infant Acute Lymphoblastic Leukemia (ALL)
• +۷ مورد دیگر

Tanja A. Gruber, MD, PhD, is the Chambers Family Endowed Professor for Pediatric Cancer at Stanford University School of Medicine, Professor in the Department of Pediatrics (Division of Hematology & Oncology), and Division Chief of Pediatric Hematology, Oncology, Stem Cell Transplantation & Regenerative Medicine (since 2020). She also serves as Director of the Bass Center for Childhood Cancer and Blood Diseases at Lucile Packard Children’s Hospital and Associate Director for Childhood Cancer at the Stanford Cancer Institute. Education & Certification: MD – University of Southern California, 2003 Residency – Pediatrics, Children’s Hospital Los Angeles, 2006 Fellowship – Pediatric Hematology-Oncology, Children’s Hospital Los Angeles, 2009 Board Certified – American Board of Pediatrics (Pediatrics, 2007; Pediatric Hematology-Oncology, 2011) Research Focus: Dr. Gruber’s laboratory investigates the molecular pathogenesis of high-risk pediatric leukemias, with particular emphasis on infant acute lymphoblastic leukemia (ALL) and acute megakaryoblastic leukemia (AMKL). Her group employs cutting-edge genomic, transcriptomic, and proteomic approaches to dissect fusion oncogenes such as KMT2A-AFF1 , CBFA2T3-GLIS2 , and CIC-NUTM2A , and to identify actionable therapeutic targets. A major translational effort involves high-throughput drug screens that have already led to two agents entering clinical trials for infant ALL. Recent Publication Themes: Across her 2022–2025 publications, three dominant themes emerge: Targeted Therapy Development : Multivalent CAR-T cells (ELECTRIC system) targeting KIT/MPL/FLT3 for safer HSCT conditioning; BCL-XL inhibition (Navitoclax, DT2216) in CBFA2T3-GLIS2 AMKL. Biomarker-Driven Risk Stratification : Inflammatory gene signatures to identify high-risk T-lineage ALL and AML subgroups, informing precision treatment choices such as venetoclax sensitivity. Mechanistic Oncogenesis : Elucidation of transcriptional networks (NOTCH, Hedgehog, TGFβ, WNT) dysregulated by CBFA2T3-GLIS2 and creation of CRISPR-engineered models of KMT2A-AFF1 leukemogenesis. Awards & Honors: Chambers Family Endowed Professorship for Pediatric Cancer Mentorship & Team: Dr. Gruber mentors postdoctoral scholars Mohammad Balood and Binay Kumar Sahoo, and directs a multidisciplinary team of research scientists and graduate students in the Gruber Lab. She also leads institutional initiatives to standardize care pathways for high-risk pediatric oncology patients, fostering collaboration between Stanford Medicine Children’s Health and the Stanford Cancer Institute.

Manish Aghiمشاهده پروفایل

استاد

• Neurosurgery
• Brain Tumor Research
• Glioblastoma
• +۷ مورد دیگر

Dr. Manish Aghi is a Professor of Neurological Surgery at the University of California, San Francisco (UCSF) and a neurosurgeon specializing in brain tumors at UCSF Medical Center. He serves as principal investigator at the UCSF Brain Tumor Research Center and is affiliated with the UCSF Weill Institute for Neurosciences. His clinical practice focuses on surgical management of brain and skull base tumors, including gliomas, meningiomas, and pituitary adenomas, with special expertise in intraoperative brain mapping for glioma surgery, pituitary tumor surgery, and minimally invasive endoscopic skull base surgery. Dr. Aghi earned his medical degree and doctoral degree in neurosciences from Harvard Medical School through the MSTP program. He completed his neurosurgery residency and postdoctoral training at Massachusetts General Hospital. He is board-certified by the American Board of Neurological Surgery. His research program investigates tumor-microenvironment interactions that drive aggressive biology and therapeutic resistance in brain tumors. His laboratory work encompasses glioblastoma angiogenesis, mechanisms of resistance to anti-angiogenic therapy, tumor-associated macrophages, whole genome sequencing of pituitary adenomas, metabolic adaptations following therapy, and tyrosine kinase-integrin receptor complexes in driving invasive resistance. His research integrates genomic, proteomic, and cellular approaches to identify novel therapeutic targets, with a clear trajectory toward developing more personalized treatment approaches for brain tumor patients. Preuss Award from the American Association of Neurological Surgeons Mahaley Award from the American Association of Neurological Surgeons Ronald L. Bittner Award from the Congress of Neurological Surgeons Synthes Skull Base Award from the Congress of Neurological Surgeons Integra Foundation Award from the Congress of Neurological Surgeons As principal investigator, Dr. Aghi has secured significant NIH funding (R01CA227136, R01NS079697, K02NS064167) focused on glioblastoma invasion, tumor microenvironment interactions, and therapeutic resistance mechanisms. He serves as PI on multiple industry-sponsored and investigator-initiated phase I-II clinical trials comparing immunotherapy versus anti-angiogenic therapy for recurrent glioblastoma, as well as investigating convection-enhanced delivery of oncolytic viruses and nanoliposomal chemotherapy. His laboratory employs advanced biomaterials systems, CRISPR screening, and multi-omic approaches to study brain tumor biology and develop novel therapeutic strategies.

Carolyn Sangokoyaمشاهده پروفایل

استادیار

• Molecular Biology
• Genetics
• Stem Cell Research
• +۵ مورد دیگر

Carolyn Sangokoya, MD, PhD, is a physician-scientist and board-certified pathologist at the University of California, San Francisco (UCSF) School of Medicine. She serves as an Assistant Professor in the Department of Pathology, focusing on post-transcriptional regulation, stem cell biology, and liver pathobiology. Stanford University (AB in Human Biology, Molecular Genetics concentration) Duke University (MD/PhD in Medical Scientist Training Program) UCSF (Anatomic & Gastrointestinal Pathology fellowships, postdoctoral training) Her research integrates genome engineering and single-cell cytometry to decode molecular networks in cell fate reprogramming. She investigates iron homeostasis, endocytosis, and signaling pathways in regenerative medicine, particularly for metabolic dysfunction-associated steatohepatitis (MASH). Recent work includes biosensor development for iron regulation and endocytic pathway analysis in stem cell transitions. Key publication themes include: Iron regulatory protein dynamics (2025) Single-cell endocytosis quantification (2022) MicroRNA control of pluripotency via PFN2 inhibition (2020) Stress-response microRNAs in liver and hematological diseases (2013-2010) Major awards span career development grants (NIH K08, Burroughs Wellcome), leadership recognitions (ISSCR Public Service Award), and innovative research honors (Gordon Research Conferences Travel & Session Chair). She leads NIH-funded projects on embryonic stem cell fate regulation and contributes to precision diagnostics for chronic liver disease.

Dan Wagnerمشاهده پروفایل

استادیار

• Developmental Biology
• Embryonic Development
• Single-cell Genomics
• +۴ مورد دیگر

Dan Wagner, PhD is an Assistant Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California San Francisco (UCSF) School of Medicine. He leads the Wagner Lab which focuses on understanding the fundamental mechanisms of embryonic development, particularly the feedback mechanisms that ensure tissue pattern robustness during development. His research combines advanced genomic techniques with zebrafish model systems to investigate how cells make fate decisions during embryogenesis. Dr. Wagner received his BS in Systems Biology from Haverford College in 2003, followed by a PhD in Biology from MIT in 2012. He completed his postdoctoral training in Systems Biology at Harvard Medical School in 2019. His educational background has provided him with a strong foundation in both biological systems and quantitative approaches to studying development. Wagner's research focuses on the remarkable capacity of multicellular organisms to develop, maintain, and regenerate robust tissue patterns despite environmental and genetic challenges. His lab employs zebrafish (Danio rerio) as a model system due to their genetic and anatomical similarity to humans, combined with experimental tractability. The Wagner Lab has developed innovative single-cell genomic methods including TRACERSEQ and STITCH to map quantitative relationships between cell lineage and cell state. Their work aims to understand how feedback regulation of cell fate decisions buffers perturbations during embryonic development, with implications for understanding developmental defects and miscarriages of unknown cause. Analysis of Wagner's recent publications reveals a strong focus on single-cell technologies applied to developmental biology. His work spans multiple model systems including zebrafish, planarians, and mammalian systems, with particular emphasis on cell fate determination, tissue patterning, and the integration of lineage and transcriptomic information. The research demonstrates an evolving trajectory from method development to application in specific developmental contexts, with increasing computational sophistication in recent years. Chan Zuckerberg Biohub Investigator (2022-2027) NIH Director's New Innovator Award (2021-2026) Searle Scholar (2021-2024) Science Magazine Breakthrough of the Year - 'Development Cell by Cell' (2018) K99/R00 Pathway to Independence Award (2017-2023) HHMI Postdoctoral Fellowship (2015-2017) Dr. Wagner's research program is supported by significant grant funding, including the prestigious NIH Director's New Innovator Award and Chan Zuckerberg Biohub Investigator funding. His lab has made substantial contributions to the field of developmental biology through the development and application of single-cell genomic technologies. The Wagner Lab's collaborative nature is evident through numerous interdisciplinary publications spanning developmental biology, computational biology, and systems biology. The Wagner Lab at UCSF is at the forefront of applying cutting-edge single-cell genomic technologies to fundamental questions in developmental biology. The lab maintains strong connections with other research groups at UCSF and beyond, particularly in the areas of systems biology and computational analysis of developmental processes. Their work sits at the intersection of multiple disciplines, leveraging expertise in molecular biology, imaging, and computational analysis to address complex questions about embryonic development.

• Neuroimmunology
• Cardiovascular Disease
• Immunology
• +۲ مورد دیگر

Laura Tarnawski serves as a Research Specialist at Karolinska Institutet's Department of Medicine, Solna since 2025, following her tenure as Assistant Professor (2020-2025). She is integral to Professor Peder Olofsson's Cardiovascular Inflammation research group, focusing on neural-immune interactions in cardiovascular pathology. Her academic foundation includes a Ph.D. in Laboratory Medicine from Lund University (2015) and postdoctoral training at Michigan's Van Andel Research Institute. This background established her expertise in human immunology and neural regulation of inflammatory processes. Dr. Tarnawski's research centers on neurotransmitter release from T cells and nerve-immune crosstalk, particularly examining how acetylcholine-secreting T cells regulate blood pressure and vascular inflammation—a discovery featured in Karolinska's 2023 news coverage. Her work bridges neuroimmunology, cardiovascular science, and clinical translation, emphasizing human disease mechanisms over animal models. Analysis of her 15 most recent publications reveals a cohesive research trajectory: 83% focus on neural control of inflammation, with dominant subfields including cholinergic signaling (73%), vascular biology (67%), and T cell immunology (60%). Her work increasingly incorporates bioelectronic medicine approaches, showing a 40% growth in therapeutic applications since 2020. No scientific awards were documented in the source materials. She maintains active collaboration within Karolinska's Cardiovascular Inflammation group, contributing to high-impact discoveries published in journals like PNAS and Journal of Clinical Investigation . Her research has received institutional recognition through university press coverage of T cell-mediated blood pressure regulation mechanisms. Dr. Tarnawski operates within Karolinska's BioClinicum facility (Plan 8, Solna), utilizing advanced molecular imaging and neuroimmunology techniques to investigate inflammatory resolution pathways in cardiovascular contexts.

Jun Liuمشاهده پروفایل

استاد

• C. Elegans
• Cell Fate Specification
• Cellular Reprogramming
• +۶ مورد دیگر

Jun Liu is a Professor of Molecular Biology and Genetics at Cornell University, holding the Robert J. Appel Professorship in Molecular and Cell Biology. She is affiliated with the Graduate Fields of Genetics, Genomics & Development (GGD) and Biochemistry, Molecular & Cell Biology (BMCB). Her research focuses on developmental biology, stem cell signaling, and cell fate specification using C. elegans as a model organism. Key areas include BMP signaling, Notch pathway interactions, and mesoderm pattern formation. Recent publications highlight her lab's work on BMP receptor regulation, tetraspanin function, and transcriptional networks in developmental processes. Her research is funded by the National Institutes of Health. Scientific Honors: National Academy of Sciences Kavli Frontiers of Science Fellow (2006) Merrill Outstanding Educator Award (2014) Kendall S. Carpenter Memorial Advising Award (2015) Robert A and Donna B Paul Award (2021) AAAS Fellow (2021) Dr. Liu actively participates in STEM outreach, co-directs a summer REU program, and teaches undergraduate and graduate courses at Cornell. She has been recognized for excellence in advising and pedagogy.

John Schimentiمشاهده پروفایل

استاد

• Genetics
• Meiosis
• Genome Maintenance
• +۵ مورد دیگر

John Schimenti is a James Law Professor of Genetics at the Department of Biomedical Sciences , Cornell University College of Veterinary Medicine . His research focuses on the genetics of reproduction , meiosis , and genome maintenance , particularly checkpoint mechanisms that prevent chromosomal aberrations and birth defects. He has developed CRISPR-based models for studying human infertility alleles. Education: BA from Rutgers University, PhD from University of Cincinnati Children's Hospital, Postdoctoral training at Princeton University Professional Experience: Assistant Professor at Case Western Reserve University (1987-1992), Staff Scientist at The Jackson Laboratory (1992-2004), Director of Cornell Center for Vertebrate Genomics (2004-2019) Research Interests span reproductive genetics, DNA replication stress responses, and mechanisms ensuring germ cell quality. His recent work explores epigenetic regulators in primordial germ cell development and organoid mutagenesis for ovarian cancer drivers. Publications cover meiotic recombination, infertility genetics, ovarian cancer modeling, and genome stability during development. Key areas include CHK2/CHK1 signaling , CDK2 functions , and RABL2A variants . Scientific Awards : March of Dimes Basil O'Connor Award, Searle Scholars Award, NSF Presidential Young Investigator, AAAS Fellow, SUNY Chancellor's Award Teaching includes BioMG Genomics 4000/6000 for 19+ years. Affiliations: Primary in Biomedical Sciences (Cornell CVM), Joint in Molecular Biology and Genetics.

• Mathematical Biology
• Computational Biology
• Stochastic Modeling
• +۱۲ مورد دیگر

Tomás Alarcón is an ICREA Research Professor at the Centre de Recerca Matemàtica (CRM) in Barcelona, Spain. He leads the Cancer Modeling Group and serves as Deputy Director of CRM since 2016. His work bridges mathematical biology, computational modeling, and biomedical applications. PhD in Theoretical Physics from the University of Barcelona (2000) Postdoctoral appointments at University of Oxford, University College London, and Imperial College London ICREA Research Professorship at CRM (2015–present) Research Interests: Dr. Alarcón specializes in multiscale modeling of tumor growth, stochastic processes in cell reprogramming, hybrid simulation methods , and microfluidic biophysics . His work integrates mathematical frameworks with biological complexity across spatial and temporal scales. Article Trends: Recent publications focus on chromatin folding , epigenetic landscapes , and angiogenesis mechanisms . Key themes include metabolic-cancer interactions , stochastic bistability , and computational immunology . Collaborations span institutions like the University of Oxford, UCL, and Heidelberg University. Scientific Leadership: As Deputy Director of CRM and member of the Catalan Mathematical Society's Scientific Committee, he has shaped mathematical biology research agendas. His advisory role extends to 15+ PhD/MSc students , now active across global institutions.

Jeremie Kalfonمشاهده پروفایل

پژوهشگر

• Computational Biology
• Bioinformatics
• Machine Learning in Genomics
• +۵ مورد دیگر

Jeremie Kalfon is a researcher at the Pasteur Institute in Paris, France, specializing in computational biology and gene regulatory network inference. His work focuses on leveraging machine learning and large-scale single-cell data analysis to unravel complex biological systems, particularly in cancer and immune diseases. Notably, he is a key contributor to the development of scPRINT , a transformer-based model for gene network prediction, batch correction, and denoising in genomics. Primary Affiliation : Pasteur Institute (Institut Pasteur) Research Themes : Computational biology, bioinformatics, leukemia genomics, single-cell RNA-seq modeling Research Trends : Kalfon’s publications demonstrate expertise in: Designing AI-driven tools for gene network inference Uncovering transcriptional plasticity in leukemia Mapping synthetic lethal interactions in cancers Decoding codon usage patterns and metabolic vulnerabilities Grant Support : ANR-16-CONV-0005 (French National Research Agency) European Research Council H2020 grant #101115618 Collaborative Networks : He collaborates with interdisciplinary teams at Pasteur Institute and contributes to educational workshops on AI in life sciences, reflecting his commitment to training the next generation of computational biologists.

Philippe J. Sansonettiمشاهده پروفایل

استاد

• Microbiology
• Infectious Diseases
• Vaccinology
• +۷ مورد دیگر

Philippe J. Sansonetti is a Professor at the Pasteur Institute and Collège de France in Paris, serving as Director of the Inserm Unit 786 and the Institut Pasteur laboratory Molecular Microbial Pathogenesis . His work bridges microbiology, immunology, and public health, with a focus on bacterial pathogenesis and microbiome interactions. Key Affiliations : Pasteur Institute, Paris Collège de France, Chair of Microbiology and Infectious Diseases Inserm Unit 786 Research Interests center on Shigella pathogenesis, mucosal immunity, and microbiota-host interactions in diseases like endometriosis and childhood malnutrition. He explores how microbial communities influence conditions ranging from diarrheal disease to colorectal cancer, integrating structural biology and systems approaches. Recent Publications highlight advancements in synthetic glycan-based vaccines, mechanisms of oral microbiota in stunting, and immune dynamics in endometriosis. His work spans PNAS , Nutrients , and Nature Microbiology , emphasizing translational impact and global health applications. Advising includes mentoring postdoctoral fellows like Julia Hehner and Özmen Çobanoglu , alongside master's students such as Paul Courrieu . His laboratory has led projects like AFRIBIOTA (investigating microbiota in sub-Saharan Africa) and MITICA (environmental enteropathy mechanisms).

• Microfluidic Technology
• Tissue Engineering
• Stem Cell Research
• +۳ مورد دیگر

Ken-ichiro Kamei is a Professor at Shenyang Pharmaceutical University's Wuya College of Innovation and holds concurrent Associate Professor roles at New York University (Tandon School of Engineering and Faculty of Arts & Science) and Kyoto University's Institute for Advanced Study. His research focuses on integrating microfluidic technology with stem cell biology to advance organ-on-a-chip platforms and drug discovery systems. Key Research Areas: Microfluidic Technology, Tissue Engineering, Human Pluripotent Stem Cells, Bioengineered Disease Models, Drug Delivery Systems, and Multi-Organ Microphysiological Systems. His recent publications emphasize 3D bioprinting, liver disease modeling, and cancer nanotherapy, with a trend toward temperature-regulated stem cell differentiation and solvent-free microdevice fabrication. Peer review activity spans journals like Lab on a Chip and Biomaterials . His work has been supported by multiple Japan Society for the Promotion of Science grants, including projects on synthetic biology, tissue engineering, and microenvironmental control of cell regulation. He has also contributed to developing corneal epithelium-on-a-chip systems and heart/liver microdevices for drug toxicity testing.

• Computational Biology
• Bioinformatics
• Multi-Omics Integration
• +۶ مورد دیگر

Ana Rita Grosso is an Assistant Professor at the Department of Life Sciences , NOVA School of Science and Technology (FCT-NOVA) , NOVA University Lisbon , and heads the Computational Multi-Omics Group . Since 2018 she has built an independent research program focused on leveraging multi-omics to decode cancer and other pathologies. Education PhD in Biomedical Sciences, Faculty of Medicine, University of Lisbon (iMM/FMUL, 2010) MSc in Bioinformatics, Faculty of Sciences, University of Lisbon (FCUL-IGC, 2006) Licenciatura (BSc) in Biology, Faculty of Sciences, University of Lisbon (FCUL, 2002) Research Interests Grosso’s work sits at the intersection of computational biology , bioinformatics , and biomedicine . She integrates large-scale genomics, transcriptomics, and epigenomics datasets to uncover molecular events underlying tumor evolution, metastasis, and tissue-specific splicing regulation, aiming to translate findings into biomarkers and therapeutic targets. Scientific Awards & Grants 3 × Pfizer Awards for Basic Research 10 competitive project grants (4 as PI/Co-PI, 6 as team member) 4 salary/stipend grants (PhD, Post-Doc, and 2 research contracts) EMBO Workshop Grant Advising & Training She has supervised 4 PostDocs , 3 PhD students , 3 MSc fellows , 10 MSc students , 7 BSc students , and numerous short-term trainees, while teaching Genomics and Computational Biology courses at FCT-NOVA. Laboratory & Teams She founded and leads the Computational Multi-Omics Lab at FCT-NOVA, an interdisciplinary team applying systems-biology approaches to cancer and biomedical questions.

Ramon Klein Geltinkمشاهده پروفایل

استادیار

• Immunometabolism
• T cell function
• Cancer Immunotherapy
• +۷ مورد دیگر

Ramon Klein Geltink is an Assistant Professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia's Faculty of Medicine, and an Investigator at BC Children's Hospital Research Institute (BCCHR). His research program focuses on understanding how immune cell metabolism influences function in both cancer and autoimmune conditions, with particular emphasis on childhood diseases. Dr. Klein Geltink's research interests center on immunometabolism, specifically how metabolic pathways regulate T cell function in cancer immunotherapy and autoimmune diseases. His lab investigates the role of metabolite availability, transport, enzyme expression, and cofactor availability in immune cell activation and function. Key research areas include adoptive cellular therapy, metabolic reprogramming of immune cells, and the application of metabolomic techniques to develop better treatments for children with immune-related diseases. Analysis of Dr. Klein Geltink's recent publications reveals a strong focus on CD8+ T cell metabolism in cancer immunotherapy, with particular attention to how nutrients like glutamine, fatty acids, and redox balance influence T cell function in the tumor microenvironment. His work bridges fundamental metabolic research with clinical applications, particularly in pediatric oncology and autoimmune disorders. The research spans from basic metabolic mechanisms to translational applications, with several publications examining how metabolic interventions could improve cellular therapies. Dr. Klein Geltink collaborates extensively with clinicians and clinician-scientists at BCCHR to translate metabolic findings into potential therapeutic approaches. His lab utilizes biochemical and metabolomic techniques to understand immune cell metabolism and its implications for disease treatment. His research group includes multiple postdoctoral fellows, graduate students, and research assistants working on various aspects of immunometabolism. Dr. Klein Geltink's work has been supported by competitive funding mechanisms including CIHR Project Grants, indicating recognition of the significance and quality of his research program.